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Abstract 
Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic 
resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. 
Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei 
City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR 
examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, 
were included retrospectively. The images were evaluated for the presence of contrast agent in intra-
hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. 
Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for 
portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes 
was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 
%) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients 
(36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in 
IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and 
duodenal excretion in 20 patients (55 %).  
Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.  
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The liver is the most metabolically complex organ 
in human body. It is large and complex organ 
with diverse functions, many of them are critical 
for survival [1]. The approaches for medical 
diagnosis and disease characterization of the 
liver and the biliary system via non-invasive 
methods have greatlyimproved over the previous 
decades due to the unending development of 
computed tomography (CT), sonography or 
ultrasound (US), nuclear medicine (NM) and 
magnetic resonance imaging (MRI) [2]. Contrary 
to CT and NM, Magnetic Resonance imaging 
does not expose the patient to any ionizing 
radiation [3]. MRI of superior body soft-tissue 
contrast was believed to provide enough 
diagnostic information for most needs, without 
the use of contrast media [4]. Gadolinium-based 
and other contrast media were, however, soon 
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considered to be of significant importance in 
disease detection and characterization [5].  
 
Gd-EOB-DTPA (gadolinium ethoxybenzyl diethyl-
enetriaminepentaacetic acid, Primovist® 0.25 
mmol/ml, Bayer Schering Pharma, Berlin, 
Germany) is a more recently approved liver- 
specific contrast agent [5,6]. It combines 
hepatocellular specificity with T1-relaxivity and 
extracellular behavior [7]. After intravenous 
injection, Gd-EOB-DTPA is first distributed into 
the extracellular space and then taken up by the 
hepatocytes.  
 
It is excreted un-metabolized form in equal 
proportions by the kidneys and ATP-dependent 
active transport in the hepatocytes to the biliary 
system. Due to which, the hepatobiliary excretory 
proportion is approximately ten times greater 
than for Gd-BOPTA. Renal excretion of Gd-EOB-
DTPA can be substituted by the hepatobiliary 






This is a retrospective study analyzing data from 
the hospital database as the study material. We 
collected all the patients’ baseline information 
including the Child Pugh scores, bilirubin level, 
and liver function. We followed guidelines given 





Institutional Review Board of Taipei City Hospital 
- Renai Branch approved the study and informed 
consent was waived. Patients with liver cirrhosis 
but with normal glomerular filtrate rate (GFR) 
were included in the analysis. All the patients 
underwent Gd-EOB-DTPA contrast-enhanced 
abdominal MR examination at Taipei City 
Hospital-Renai Branch from January 2011 to 
August 2012. Dataset of patient with ages equal 
or greater than 20 years were included in the 
study as the safety and effectiveness of Gd-
EOB-DTPA has not been established in pediatric 
patients. 
 
A total of 47 patients were enrolled in this study. 
Clinical and demographic information of the 
patients in the present study is illustrated in 
Table 1.  
 
Patients younger than 18 years or with abnormal 
glomerular filtration rate were excluded from the 
study. Also Patients who had any contra-
indication to MRI (cardiac pacemaker, 
ferromagnetic implants, etc.) were excluded as 
well. 
 
Table 1: Patient demographic data and clinical 
information of the patients 
 
Age range (mean age) 22–80 years (57.3years) 
Sex (M/F) 32/15 
Total bilirubin  2.11mg/dL 
AST/ALT 46/40 IU/L 
Creatinine 0.98 mg/dL 
CBD diameter  4.84 mm (2.91- 10.86) 
Hepatitis (n) B (40) 
 C (4) 
Alcoholic (2) 
B +Alcoholic (1) 






All MRI examinations of the liver of the enrolled 
patients were performed with Achieva 1.5T A-
Series MRI Scanner from Philipsphased-array 
body coil. Prior to contrast agent administration, 
turbo spin-echo (TSE) T2WI (TR/TE: 1000 – 
1800/110 milliseconds; Slice thickness 8mm; 
Gap 0.8 mm; Matrix, 192×256; TSE factor, 24; 
number of average [NEX], 2; Flip angle 90°; 
FOV, 38-40 cm) without and with fat saturation, 
and coronal T2WI were obtained under 
respiratory trigger. Dual T1WI (TR/TE: 
180/2.3/4.6; Slices thickness 8mm; Matrix, 
192×256; NEX, 1; Flip angle 10°; FOV, 38-40 
cm) and fat sat T1WI were performed during one 
breath hold. Automatic shimming has been used 
for fat suppression imaging to maximize 
magnetic field homogeneity. Flow compensation 
is also used for the same purpose.  
 
For the contrast-enhanced MRI, all the patients 
received a dose of 0.025 mmol/kg or 10 ml of Gd 
– EOB-DTPA (Primovist; Bayer Schering 
Pharma, Osaka, Germany). The contrast agent 
was injected as a bolus at a speed of nearly 2 
ml/s through peripheral veins. Dynamic 3D T1-
weighted fast field echo (FFE) sequence (TR/TE: 
5 - 10/3.3 ms; Slice thickness 5 mm; Matrix, 192 
× 256; NEX, 1; Flip angle 10°; FOV, 38 - 40 cm) 
was carried out before, 18 - 20 s (arterial phase, 
AP), 50 ~ 55 s (portal venous phase, PP), 85 ~ 
90 s (venous phase, VP) following the contrast 
agent injection. In addition, three delay phase 
images (180 s, 20 min and 30 min after the 




The images were evaluated for the presence of 
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contrast agent in the intra-hepatic bile ducts 
(IHD), the common bile duct (CBD), the 
gallbladder and the duodenum in AP, PP, VP 
and three delayed phases. The images were 
evaluated by the same radiologist. He had to 





The data has been presented as mean ± 
standard deviation (SD). Each experiment was 
repeated at least 3 times. Statistical analysis was 
performed using SPSS version 19 for one-way 
analysis of variance (ANOVA) with p < 0.05 
being significant, was used to determine whether 
there was significant difference in time of first 
appearance of contrast agent in the individual 
segments of the hepatobiliary tract, with the 
cirrhotic degree (according to Child-Pugh score) 
and the bilirubin level (according to mean value 




The demographic patient data and clinical 
indications for the abdominal MR examinations 
are provided in Table 1. Out of the 47 patients, 
gall bladder (GB) was not visible in 9 patients, 4 
out of 9 patients had cholecystectomy. The GB 
might have been removed due to complications 
associated with the gall bladder i.e. gall stones, 
and gall bladder cancer etc. The mean CBD 
diameter was 4.84 mm.  
The optimal time of arterial phase was from 18 - 
20 s after injection, while for the portals, 50 - 55 s 
after injection for the venous phase. The mean 
time for opacification was after 20 min contrast 
injection in 39 patients (39/47, 83 %) at the IHD 
in 37 patients (37/47, 78 %) at the CBD. Gall 
bladder reflux was visible in 26 (26/47, 43 %) and 
17 patients (17/47, 36 %) at the duodenal. After 
30 min, Gd – EOB-DTPA could still be detected 
in 6 patients (6/47, 13 %) at the IHD and in 7 
patients (7/47, 15 %) at the CBD. Gallbladder 
reflux was visible in 10 patients (10/47, 21 %), 
duodenal excretion in 26 patients (26/47, 55 %) 
respectively as shown in Table 2. 
 
On visualization of the biliary tree, the distribution 
was not statistically significant (p < 0.05) 
between bilirubin level and visualization of the 
biliary tree as shown on Table 3. 
 
On Visualization of Gd – EOB-DPTA contrast in 
IHD and CBD for Patients with different bilirubin 
level, the excretion of Primovist in the biliary tree 
is affected by the bilirubin level. After 30 min, the 
p value was significant (p=0.043) in comparison 
with group 1 and group 3. The p value was not 
significant, between group 1 and 2 (p=0.27) after 
30 min of injection. The p-value was not 
statistically significant between group 2 and 
group 3, after 30 min post injection (p=0.226) as 
provided in Table 4. 
 
In group three, where the bilirubin level is more 
than 2 mg / dl 30 minutes’ post injection, the 
visualization level is 40 % as shown in Figure 1. 
This illustrates the severity of liver cirrhosis can 
influence the uptake and excretion of the contrast 
agent. Dahlqvistet.al, demonstrated that impaired 
hepatobiliary function severely influences the 
hepatic uptake of Gd – EOB - DTPA when they 
did a study on 31 patients on how to quantify the 
hepatocyte specific uptake of Gd - BOPTA and 
Gd – EOB - DTPA using dynamic contrast 
enhanced (DCE) MRI [19]. 
 




AP PP VP 3min 20min 30min 
IHD  0 0 *2/0/0 0 *36/3/0 *2/2/2 
CBD  0 0 *3/0/0 0 *34/3/0 *3/2/2 
GB  0 0 *1/0/0 0 *24/2/0 *5/3/2 
Duodenum  0 0 0 *1/0/0 *17/0/0 *19/5/2 
 
 




IHD CBD GB Duodenum 
No. Bilirubin No. Bilirubin No. Bilirubin No. Bilirubin 
 2 0.75±0.35 3 0.79±0.26 1 0.87 0 VP 
3 min  0 0 0 0 0 0 1 0.87 
20 min  39 2.07±5,59 37 2.13±5.74 26 2.44±6.86 17 3.11±8.48 
30 min  6 2.85±3.69 7 2.58±3.44 10 2.16±2.91 26 1.57±1.85 
P-value   0.885  0.888  0.964  0.653 
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No. indicates number of patients 
 
Table 4: Visualization of Gd – EOB-DPTA contrast in IHD and CBD for patients with different bilirubin level 
 
Variable Group 1 (27) 
(>1.2 mg/dl) 
Group 2 (15) 
(1.2 - 2.1 mg/dl) 
Group 3 (5) 
(>2 mg/dl) 
Venous phase IHD 2 - - 
CBD 3 - - 
3 min IHD - - - 
CBD - - - 
20 min IHD 23 12 3 
CBD 21 12 3 
30 min IHD 2(2/27) 7.4% 3(3/15) 20% 2(2/5) 40% 





Post contrast 20 min in axial and MIP 3D 
images 
 
(c)   
(d)   
Post contrast 30 min in axial and MIP 3D images 
 
Figure 1: Appearance of Gd-EOB-DTPA in the 
hepatobiliary System after 20 and 30 min in Subfigure 
a, b, c and d 
DISCUSSION 
 
Currently, data regarding transit times of Gd-
EOB-DTPA via the biliary excretion route in the 
patients is limited, as most of the ‘delayed 
imaging time course data’ have been gathered 
from healthy volunteers. Our analysis which was 
performed on the patients with liver cirrhosis 
showed no difference in terms of transit times 
when compared to the other studies conducted 
on patients with normal liver. Kristina I. Ringe et 
al evaluated the hepatobiliary transit times of Gd-
EOB-DTPA in 61 patients with normal liver 
function [14]. After 20 min of contrast initiation, 
Gd-EOB-DTPA was visible in the IHD and CBD 
in all patients. 
 
In our study, 40 out of 47 patient were Child 
Pugh A. This might be the reason that there is no 
difference between our study and Kristina’s 
study. In a phase I clinical evaluation, Hamm et 
al detected enhancement of the CBD as early as 
10 min after contrast administration in 44 healthy 
volunteers [10]. Dahlström et al, who also 
evaluated the biliary excretion of Gd-EOB-DTPA 
in healthy subjects, later on confirmed these 
findings [15]. Bollow et al investigated the time 
course of contrast enhancement in the bile ducts 
in 16 healthy volunteers at 4 different doses of 
Gd-EOB-DTPA. Initial enhancement of the CBD 
was seen at a mean time of 10±4min post 
contrast [11]. Our results are in line with the 
previously reported transit times for the 
intrahepatic bile ducts and the CBD but in 
patients with normal liver function which basically 
means that Gd-EOB-DTPA is not affected by 
liver disease. The number of patients in our study 
is small and the majority of the patients 
represented were only mildly affected by the 
disease. Patients with child Pugh C seemed to 
influence liver excretion of the contrast media. 
This confirms previous studies which indicate a 
tendency towards decreased diagnostic 
capability with the severity of cirrhosis. 
 
Frank et al compared the quality of biliary duct 
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visualization using Gd-EOB-DTPA enhanced 
magnetic resonance cholangiography in 40 
adults with liver cirrhosis and 20 adults with 
normal liver parenchyma [18]. The overall quality 
was rated as sufficient for anatomical 
visualization of the biliary tree in all individuals of 
the control group 20 min after Gd-EOB-DTPA 
administration, but in only 16/40 patients (40 %) 
of the cirrhosis group within 30 min after 
administration.  Analysis revealed non-sufficient 
visualization of the biliary tree 20 min after Gd – 
EOB-DTPA administration, were total serum 
bilirubin levels ≥30 μmol/l.  
 
The excretion of Primovist in the biliary tree is 
affected by bilirubin level in group 3 where the 
bilirubin level is more than 2mg/dl 30 minutes 
post injection. The visualization level is 40 
percent. This illustrates that the severity of liver 
cirrhosis can influence the uptake and excretion 
of the contrast agent. Dahlqvist et al 
demonstrated that impaired hepatobiliary 
function severely influences the hepatic uptake of 
Gd-EOB-DTPA when they did a study on 31 
patients on how to quantify the hepatocyte-
specific uptake of Gd-BOPTA and Gd-EOB-
DTPA using dynamic contrast-enhanced (DCE) 
MRI [19]. 
 
Primovist can be detected in most of the patients 
after 20 minutes with child Pugh A/B/C in this 
study. In the venous phase we can detect 
Primovist in patients 2/3/1, IHD, CBD, GB 
respectively early in the phase. It is important to 
note that all these patients have child Pugh A. 
Patients with child Pugh B and C seemed to 
influence the liver excretion of the contrast 
media. Our results were pretty similar to a study 
by Tsutomu Tamada that showed similar results 
after the MR image obtained in an 80-year-old 
woman with cirrhosis (Child-Pugh C) acquired 20 




One weakness of this study is the different 
distribution of the number of the study population 
in Child-Pugh class (A, B and C) with a high 
number of population in (A) compared with very 
low population number in (B and C). This may 
have led to failure in having an insignificant p-
value. As this was a retrospective study, the 
exact point of time for acquisition of the delayed 




It can be concluded that liver cirrhosis patients 
show no significant changes with regards to 
transit times when compared to normal patients. 
Despite the difficulties in quantification of liver 
function, GD – EOB- DTPA enhanced MR 
imaging (MRI) offers a unique opportunity to 
combine qualitative and quantitative 
morphological and functional information that 
may improve the assessment of focal liver 
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